Observational studyJournal of neurology2024
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
Observational study in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.Neurology · 2025Trial
- Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.Annals of clinical and translational neurology · 2024Trial
- Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model.PharmacoEconomics - open · 2026Article
- Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.Journal of neurology · 2026Observational
- Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis.Journal of neurology · 2026Article
- Ketoanalogue-Supplemented Low-Protein Diet in Patients with Stage 4+ Chronic Kidney Disease in Italy: A Cost-Utility Analysis.Nutrients · 2026Article
- Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom.Neurology and therapy · 2026Article
- Use of subcutaneous natalizumab in routine care - Final results of a non-interventional, observational study (SISTER) in Germany and Austria.Therapeutic advances in neurological disorders · 2026Article
- Article
- Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis.PharmacoEconomics · 2025Article
- Cost-effectiveness of a ketoanalogue-supplemented very low-protein diet in CKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- The Impact of In-Hospital Disease Modifying Treatments on Mental and Physical Burden in Caregiver of Patients With MS.Annals of clinical and translational neurology · 2025Article
- Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.Journal of neurology · 2025Article
- Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America.Therapeutic advances in neurological disorders · 2025Article
- Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.Therapeutic advances in neurological disorders · 2025Review
- Patient Preference and Time Allocation Associated with Transition from Intravenous to Subcutaneous Administration of Natalizumab (Tysabri) in Patients with Relapsing Remitting MS - A Questionnaire Study.Patient preference and adherence · 2025Article
- Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (TysabriNeurology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEASIER is a multicenter, observational, cross-sectional study investigating the consumption of healthcare resources, including healthcare professional (HCP) active working time, the costs associated with the current natalizumab intravenous (IV) administration, and the potential impact of the adoption of subcutaneous (SC) route.
methodsThe EASIER study has three parts: (1) time and motion study to measure healthcare resources and working time needed for natalizumab IV administration using a digital data collection tool operated directly by HCPs; (2) HCP structured questionnaire-based estimation of the potential impact of natalizumab SC vs. IV administration; and (3) patient survey on the burden of natalizumab administration.
resultsNine Italian multiple sclerosis (MS) centers measured 404 IV natalizumab administration procedures and administered 26 HCP questionnaires and 297 patient questionnaires. Patients had a mean of 52 (range 1-176) previous IV administrations and spent a mean (median, IQR) of 152 (130, 94-184) minutes in the center per each IV procedure, with IV infusion covering 50% of the total. Including patient travel time, an average of 5 h was dedicated to each IV administration. Active working time by HCP amounted to 29 min per IV administration procedure, 70% of which by nursing staff. With adoption of the SC route, HCPs estimated a 50% reduction in patient procedure time and 55% lower HCP active working time. This translated into a 63% cost reduction for the MS center per natalizumab administration procedure.
conclusionsSC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.